ATC codes:
Pending
Indication
Chronic hepatitis C
ICD11 code:
1E91.1
INN
Ravidasvir
Medicine type
Chemical agent
List type
Core
Additional notes
Pangenotypic when used in combination with sofosbuvir.
Formulations
Oral > Solid > tablet:
200 mg
EML status history
First added in 2023
(TRS
1049)
Sex
All
Age
Adolescents and adults
Therapeutic alternatives
Medicines within the same pharmacological class can be used
Therapeutic alternatives limitations
Pangenotypic direct-acting antiviral combinations
Patent information
Main patent is active in several jurisdictions. For more information on specific patents and
license status for developing countries visit www.MedsPal.org
Read more
about patents.
Wikipedia
DrugBank
Summary of evidence and Expert Committee recommendations
The Expert Committee recommended the inclusion of ravidasvir on the core list of the EML as a therapeutic alternative under the square box listing for pangenotypic direct-acting antivirals for the treatment of chronic hepatitis C virus infection in adults. Ravidasvir is pangenotypic when used in combination with sofosbuvir. The recommendation was made based on evidence of effectiveness and safety, similar to that seen with other pangenotypic direct-acting antiviral regimens.